BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of$ 0.24. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -16.67%. A quarter ago, it was expected that this drugmaker would post a loss of$ 0.25 per share when it actually produced a loss of $0.19, delivering a surprise of 24%.Over the last four quarters, the company has ...